Disodium Cromoglicate(インタ-ル)2%点鼻液剤による鼻アレルギ-の治療-1-Pilot trial

概要

論文の詳細を見る
A newly developed 2% nasal solution of disodium cromoglicate (DSCG) was studied in patients with perennial nasal allergy to determine the optimum dose, duration of effect, clinical effectiveness, clinical safety and convenience of administration.The optimum dose of DSCG was examined by protective effect on antigen induced nasal reaction.There was no difference among 1, 2 and 4 squeezes per nostril regarding protective effect on nasal allergic reaction.When the duration of action of DSCG was examined, it was found that the protective effect on antigen induced nasal reaction lasted on an average of 3.4 hours.In an open study of DSCG, effectiveness was obtained in 83.3% of the patients, and onset of effect was within 2 weeks.Subjectively, nasal blocking showed the greatest improvement and objectively, watery secretion, swelling of the mucous membrane and eosinophilia improved markedly. There were no side effects attributed to DCSG solution and the administration is so easily facilitated that even young children could operate the apparatus without difficulty.In a cross-over comparative study of the solution and the powder form, the effectiveness and safety of the solution were almost equal to those of the powder form. The solution was superior to the powder form in convenience of administration and pocketability. Therefore, the solution seems to be suited for use in young children rather than the powder form.However, the solution had the disadvantage in having to be administered more often (6 times daily) than the powder form (4 times daily).In summary, DSCG solution (1 squeeze/nostril, 3-6 times/day) had the same effect as the powder form and there were few side effects. The solution was more easily applied than the powder form, and is particularly suitable for use in young children.

Disodium Cromoglicate(インタ-ル)2%点鼻液剤による鼻アレルギ-の治療-1-Pilot trial

スポンサーリンク

概要

著者

関連論文

スポンサーリンク